Corcept Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 730

Employees

  • Stock Symbol
  • CORT

Stock Symbol

  • Share Price
  • $63.66
  • (As of Friday Closing)

Corcept Therapeutics General Information

Description

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Contact Information

Website
corcept.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 101 Redwood Shores Parkway
  • Redwood City, CA 94065
  • United States
+1 (650)
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 101 Redwood Shores Parkway
  • Redwood City, CA 94065
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corcept Therapeutics Stock Performance

As of 20-Nov-2026, Corcept Therapeutics’s stock price is $63.66. Its current market cap is $6.96B with 109M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$63.66 $64.92 $28.66 - $126.38 $6.96B 109M 1.26M $1.51

Corcept Therapeutics Financials Summary

As of 30-Sep-2026, Corcept Therapeutics has a trailing 12-month revenue of $964M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 12,157,402 3,245,225 4,906,074 2,993,082
Revenue 963,647 761,407 675,040 482,375
EBITDA 113,879 46,687 138,287 109,644
Net Income 162,292 99,652 141,209 106,140
Total Assets 1,034,027 836,651 840,553 621,517
Total Debt 8,991 6,107 6,936 151
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corcept Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Corcept Therapeutics‘s full profile, request access.

Request a free trial

Corcept Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medica
Pharmaceuticals
Redwood City, CA
730 As of 2025

Pasadena, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Corcept Therapeutics Competitors (52)

One of Corcept Therapeutics’s 52 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA
Cytokinetics Formerly VC-backed South San Francisco, CA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA
Esperion Therapeutics Private Equity-Backed Ann Arbor, MI
You’re viewing 5 of 52 competitors. Get the full list »

Corcept Therapeutics Patents

Corcept Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026059904-A1 Concomitant administration of cyp3a4 inducers and mifepristone Pending 10-Sep-2024
US-20260069586-A1 Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome Pending 10-Sep-2024
WO-2026059903-A1 Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome Pending 10-Sep-2024
WO-2025265030-A1 Concomitant administration of selective glucocorticoid receptor modulator relacorilant and p-glycoprotein substrates Pending 21-Jun-2024
WO-2025265030-A9 Concomitant administration of selective glucocorticoid receptor modulator relacorilant and p-glycoprotein substrates Pending 21-Jun-2024 A61P3/10
To view Corcept Therapeutics’s complete patent history, request access »

Corcept Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Corcept Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

33.99 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Corcept Therapeutics’s complete esg history, request access »

Corcept Therapeutics FAQs

  • When was Corcept Therapeutics founded?

    Corcept Therapeutics was founded in 1998.

  • Where is Corcept Therapeutics headquartered?

    Corcept Therapeutics is headquartered in Redwood City, CA.

  • What is the size of Corcept Therapeutics?

    Corcept Therapeutics has 730 total employees.

  • What industry is Corcept Therapeutics in?

    Corcept Therapeutics’s primary industry is Pharmaceuticals.

  • Is Corcept Therapeutics a private or public company?

    Corcept Therapeutics is a Public company.

  • What is Corcept Therapeutics’s stock symbol?

    The ticker symbol for Corcept Therapeutics is CORT.

  • What is the current stock price of Corcept Therapeutics?

    As of 20-Nov-2026 the stock price of Corcept Therapeutics is $63.66.

  • What is the current market cap of Corcept Therapeutics?

    The current market capitalization of Corcept Therapeutics is $6.96B.

  • What is Corcept Therapeutics’s current revenue?

    The trailing twelve month revenue for Corcept Therapeutics is $964M.

  • Who are Corcept Therapeutics’s competitors?

    Arrowhead Pharmaceuticals, Cytokinetics, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Esperion Therapeutics are some of the 52 competitors of Corcept Therapeutics.

  • What is Corcept Therapeutics’s annual earnings per share (EPS)?

    Corcept Therapeutics’s EPS for 12 months was $1.51.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process